Stock comparison
Harrow Health
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HROW
Harrow Health
Market cap
$1.15B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HROW | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 77B | LMAT |
| Benjamin Graham | 73D | 89A | LMAT |
| Philip Fisher | 65C | 81C | LMAT |
| Peter Lynch | 75C | 67B | HROW |
| Joel Greenblatt | 47D | 56D | LMAT |
| Charlie Munger | 55D | 68D | LMAT |
| Terry Smith | 49D | 69D | LMAT |
Side-by-side metrics
| Metric | HROW | LMAT |
|---|---|---|
| Market cap | $1.15B | $2.32B |
| P/E (TTM) | - | 37.1x |
| EV/EBIT | 35.2x | 36.6x |
| ROIC (TTM) | 8.55% | 9.43% |
| Gross margin | 74.11% | 72.39% |
| Net margin | -5.57% | 24.35% |
| Revenue CAGR 5y | 39.22% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 10.5x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HROW leads on
- P/E (TTM)-vs 37.1x+148%
- Revenue CAGR 5y39.22%vs 12.75%+67%
LMAT leads on
- Net margin24.35%vs -5.57%+123%
- Dividend yield0.84%vs 0.0%+100%
- Debt / Equity0.5xvs 10.5x+96%
- Market cap$2.32Bvs $1.15B+50%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.